Speaker
Description
Bioprinting technologies, including those developed by our group, have already entered the stage of clinical application. However, most of these achievements remain in the Proof of Concept and/or phaseI/II, and many challenges must be overcome before bioprinting can become a widely adopted medical practice. One critical aspect is the series of steps that follow the industrial printing process—commonly referred to in the printing industry as “post-printing.” In traditional printing, commercial success does not depend on printing alone but also on subsequent processes such as finishing, binding, marketing, and distribution. Similarly, in our field, while research has largely focused on pre-printing preparation and the printing itself, the path to clinical adoption requires greater attention to the post-bioprinting phase. By highlighting this analogy, the aim of this session is to bring awareness to the diverse post-bioprinting processes that are indispensable for translating printed constructs into functional and clinically relevant therapies. Through this session, we hope to encourage the research community to expand its perspective beyond the printing step and accelerate progress toward the realization of bioprinting as a standard medical practice.